Treatment of systemic JIA: When do we need a biologic? Real world data of a single center

Abstract

Objectives

This paper aimed to present real-world data of treatment results of a single center in patients with systemic Juvenile Idiopathic arthritis (SJIA), in which methotrexate (MTX) along with glucocorticoids was preferred as the first-line treatment option.

Methods

The medical records of 50 patients (58 episodes) with SJIA were evaluated. All patients with SJIA were hospitalized and were given high dose glucocorticoid treatment along with subcutaneous MTX. A biological agent was added in which disease activity control was not available with MTX.

Results

Forty-one (70.6%) of 58 episodes were controlled by MTX, following discontinuation of steroids, while a biologic drug was needed in the remaining 17 (29.4%) episodes. The patients receiving MTX were divided into two groups: Group I (n = 36) (41 episodes) consisted of patients receiving MTX alone, and Group II (n = 14) (17 episodes) consisted of patients receiving MTX plus a biologic agent. Group I was dominated by the monocyclic course (56.1%), whereas group II was dominated by persistent course (70.6%). The initial erythrocyte sedimentation rate (82 vs 67 mm/h) and neutrophil/lymphocyte ratio (8.6 vs 4.1) were significantly elevated in the Group II (p = .003 and p = .007, respectively). NLR of 5.23 predicted the requirement for biological agents with a sensitivity of 66.7%, specificity 71.4%. Odds ratio for NLR ≥ 5.23 was 5.1 in Group II.

Conclusion

This study suggested that MTX was highly successful in cases with any SJIA episode, regardless of whether arthritis was present or not, even in cases presenting with MAS. A biologic drug is needed, if NLR is greater than 5.23.

Key messages

• High dose glucocorticoids with high dose SC methotrexate are the initial treatment option in systemic JIA.

• In glucocorticoid dependent patients, where methotrexate is ineffective, biologic therapy is mandatory.

• A neutrophil/lymphocyte ratio greater than 5.23 predicts the need for early biologic treatment.

• High dose S.C. MTX could be an option as an initial treatment in SJIA, especially biologics are not available.

Keywords:

• Systemic juvenile idiopathic arthritis
• treatment
• methotrexate
• biologic agent
• neutrophil/lymphocyte ratio

Conflict of interest

None.